Andrew Hollman Meyer is Chief Business Officer at Janux Therapeutics, Inc. (JANX). They have made 3 open-market trades across 1 company since 2024, most recently 2026-01-02.
CIK 0001864159
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JANX | 83,095 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-01-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JANX | SELL | 2026-01-02 | 2026-01-02 | $13.73 | $26K | +4.1% | +3.1% | +9.1% |
| JANX | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $32.98 | $110K | -11.3% | -19.9% | -21.2% |
| JANX | SELL · 10b5-1 | 2025-11-14 | 2025-11-14 | $30.00 | $100K | +19.8% | -47.8% | -54.6% |
| JANX | SELL · 10b5-1 | 2025-10-28 | 2025-10-30 | $30.06 | $1.0M | +2.7% | +21.0% | -50.4% |
| JANX | SELL · 10b5-1 | 2025-05-01 | 2025-05-02 | $31.99 | $200K | -24.6% | -16.6% | -20.0% |
| JANX | SELL · 10b5-1 | 2025-04-21 | 2025-04-23 | $30.00 | $100K | -5.3% | -19.9% | -16.2% |
| JANX | SELL · 10b5-1 | 2025-03-03 | 2025-03-05 | $32.03 | $185K | +2.4% | -16.3% | -17.4% |
| JANX | SELL · 10b5-1 | 2025-02-03 | 2025-02-05 | $42.20 | $243K | -15.7% | -30.4% | -42.0% |
| JANX | SELL | 2025-01-02 | 2025-01-03 | $54.79 | $1.4M | -23.9% | -21.2% | -49.4% |
| JANX | SELL | 2024-09-27 | 2024-09-27 | $45.96 | $2.3M | +1.2% | +19.6% | +21.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.